Advertisement

Melatonin and Benzodiazepine/Z-Drug Abuse

  • Daniel E. Vigo
  • Daniel P. Cardinali
Chapter

Abstract

A temporal relationship between the nocturnal rise in melatonin secretion and the increase in sleep propensity at the beginning of the night, coupled with the sleep-promoting effects of exogenous melatonin, supports the view that melatonin is involved in the regulation of sleep. Both meta-analyses and consensus agreements give credibility to the therapeutic use of melatonin in sleep disorders. Administration of melatonin will cue the circadian phase of sleep/wake cycles in a variety of disorders including jet lag problems, shift work maladaptation, advanced and delayed sleep phase disorders, major affective disorder, seasonal affective disorder, and disrupted rhythms in attention deficit hyperactivity disorder, autism, and schizophrenia. This action is attributed to MT1 and MT2 melatonin receptors present in the hypothalamic suprachiasmatic nucleus (SCN) and in other brain areas. Almost every single neuron in the SCN contains GABA, and many results in animals point out to a melatonin interaction with GABA-containing neurons. In addition, central-type benzodiazepine (BZD) antagonism that obliterates GABAA receptor function blunted melatonin behavioral effects including sleep. The sleep-promoting activity of melatonin is relevant because the BZD and type Z-drugs usually prescribed as sleep promoters have many adverse effects, such as next-day hangover, dependence, and impairment of memory. This chapter discusses available data on the efficacy of melatonin to curtail chronic BZD/Z-drug use in insomnia patients.

Keywords

Insomnia Melatonin Benzodiazepines Z-drugs Drug abuse 

Notes

Acknowledgments

Studies in authors’ laboratory were supported by grants PICT 2007 01045 and 2012 0984 from the Agencia Nacional de Promoción Científica y Tecnológica, Argentina.

References

  1. 1.
    Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, Britton TC, Crowe C, Dijk DJ, Espie CA, Gringras P, Hajak G, Idzikowski C, Krystal AD, Nash JR, Selsick H, Sharpley AL, Wade AG. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol. 2010;24:1577–601.PubMedGoogle Scholar
  2. 2.
    Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc GL, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Goncalves M, Hertenstein E, Jansson-Frojmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weess HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675–700.PubMedGoogle Scholar
  3. 3.
    Pillai V, Roth T, Mullins HM, Drake CL. Moderators and mediators of the relationship between stress and insomnia: stressor chronicity, cognitive intrusion, and coping. Sleep. 2014;37:1199–208.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Cedernaes J, Schioth HB, Benedict C. Determinants of shortened, disrupted, and mistimed sleep and associated metabolic health consequences in healthy humans. Diabetes. 2015;64:1073–80.PubMedGoogle Scholar
  5. 5.
    Landry GJ, Liu-Ambrose T. Buying time: a rationale for examining the use of circadian rhythm and sleep interventions to delay progression of mild cognitive impairment to Alzheimer’s disease. Front Aging Neurosci. 2014;6:325.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Kessler RC, Berglund PA, Coulouvrat C, Fitzgerald T, Hajak G, Roth T, Shahly V, Shillington AC, Stephenson JJ, Walsh JK. Insomnia, comorbidity, and risk of injury among insured Americans: results from the America Insomnia Survey. Sleep. 2012;35:825–34.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Stone KL, Blackwell TL, Ancoli-Israel S, Cauley JA, Redline S, Marshall LM, Ensrud KE. Sleep disturbances and risk of falls in older community-dwelling men: the outcomes of Sleep Disorders in Older Men (MrOS Sleep) Study. J Am Geriatr Soc. 2014;62:299–305.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Neikrug AB, Ancoli-Israel S. Sleep disorders in the older adult – a mini-review. Gerontology. 2010;56:181–9.PubMedGoogle Scholar
  9. 9.
    Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 2. Management of sleep disorders in older people. CMAJ. 2007;176:1449–54.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Wolkove N, Elkholy O, Baltzan M, Palayew M. Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ. 2007;176:1299–304.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Fetveit A. Late-life insomnia: a review. Geriatr Gerontol Int. 2009;9:220–34.PubMedGoogle Scholar
  12. 12.
    Boyle N, Naganathan V, Cumming RG. Medication and falls: risk and optimization. Clin Geriatr Med. 2010;26:583–605.PubMedGoogle Scholar
  13. 13.
    Faught E. Monotherapy in adults and elderly persons. Neurology. 2007;69:S3–9.PubMedGoogle Scholar
  14. 14.
    Wills P, Claesson CB, Fratiglioni L, Fastbom J, Thorslund M, Winblad B. Drug use by demented and non-demented elderly people. Age Ageing. 1997;26:383–91.PubMedGoogle Scholar
  15. 15.
    Clay E, Falissard B, Moore N, Toumi M. Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and Z-drugs consumption in nine European countries. Eur J Clin Pharmacol. 2013;69:1–10.PubMedGoogle Scholar
  16. 16.
    Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev. 2005;9:51–65.PubMedGoogle Scholar
  17. 17.
    Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007;21:995–1018.PubMedGoogle Scholar
  18. 18.
    Cardinali DP, Srinivasan V, Brzezinski A, Brown GM. Melatonin and its analogs in insomnia and depression. J Pineal Res. 2012;52:365–75.PubMedGoogle Scholar
  19. 19.
    Lavie P. Melatonin: role in gating nocturnal rise in sleep propensity. J Biol Rhythm. 1997;12:657–65.Google Scholar
  20. 20.
    Cardinali DP, Pandi-Perumal SR, Niles LP. Melatonin and its receptors: biological function in circadian sleep-wake regulation. In: Monti JM, Pandi-Perumal SR, Sinton CM, editors. Neurochemistry of sleep and wakefulness. Cambridge, UK: Cambridge University Press; 2008. p. 283–314.Google Scholar
  21. 21.
    Golombek DA, Pevet P, Cardinali DP. Melatonin effects on behavior: possible mediation by the central GABAergic system. Neurosci Biobehav Rev. 1996;20:403–12.PubMedGoogle Scholar
  22. 22.
    Cardinali DP, Golombek D, Rosenstein RE, Brusco LI, Vigo DE. Assessing the efficacy of melatonin to curtail benzodiazepine/Z drug abuse. Pharmacol Res. 2016;109:12–23.PubMedGoogle Scholar
  23. 23.
    Downing SS, Lee YT, Farb DH, Gibbs TT. Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA(A) receptors supports an allosteric model of modulation. Br J Pharmacol. 2005;145:894–906.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Katzung GB, Trevor AJ. Basic & clinical pharmacology. 13th ed. New York: McGraw-Hill Education; 2015.Google Scholar
  25. 25.
    Mandrioli R, Mercolini L, Raggi MA. Metabolism of benzodiazepine and non-benzodiazepine anxiolytic-hypnotic drugs: an analytical point of view. Curr Drug Metab. 2010;11:815–29.PubMedGoogle Scholar
  26. 26.
    Winkler A, Auer C, Doering BK, Rief W. Drug treatment of primary insomnia: a meta-analysis of polysomnographic randomized controlled trials. CNS Drugs. 2014;28:799–816.PubMedGoogle Scholar
  27. 27.
    Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–49.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Schroeck JL, Ford J, Conway EL, Kurtzhalts KE, Gee ME, Vollmer KA, Mergenhagen KA. Review of safety and efficacy of sleep medicines in older adults. Clin Ther. 2016;38:2340–72.PubMedGoogle Scholar
  29. 29.
    Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf. 2009;32:735–48.PubMedGoogle Scholar
  30. 30.
    Cummings C. Melatonin for the management of sleep disorders in children and adolescents. Paediatr Child Health. 2012;17:331–6.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Pin AG, Merino AM, de la Calle CT, Hidalgo Vicario MI, Rodriguez Hernandez PJ, Soto IV, Madrid Perez JA. Consensus document on the clinical use of melatonin in children and adolescents with sleep-onset insomnia. An Pediatr (Barc). 2014;81:328–9.Google Scholar
  32. 32.
    Bruni O, Alonso-Alconada D, Besag F, Biran V, Braam W, Cortese S, Moavero R, Parisi P, Smits M, Van der Heijden K, Curatolo P. Current role of melatonin in pediatric neurology: clinical recommendations. Eur J Paediatr Neurol. 2015;19:122–33.PubMedGoogle Scholar
  33. 33.
    Bruni O, Angriman M, Calisti F, Comandini A, Esposito G, Cortese S, Ferri R. Practitioner review: treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatry. 2018;59(5):489–508.PubMedGoogle Scholar
  34. 34.
    Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005;9:41–50.PubMedGoogle Scholar
  35. 35.
    Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013;8:e63773.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, Baker G, Klassen TP, Vohra S. The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis. J Gen Intern Med. 2005;20:1151–8.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Matheson E, Hainer BL. Insomnia: pharmacologic therapy. Am Fam Physician. 2017;96:29–35.PubMedGoogle Scholar
  38. 38.
    Lerner AB, Case MD. Melatonin. Fed Proc. 1960;19:590–2.Google Scholar
  39. 39.
    Golombek DA, Pandi-Perumal SR, Brown GM, Cardinali DP. Some implications of melatonin use in chronopharmacology of insomnia. Eur J Pharmacol. 2015;762:42–8.PubMedGoogle Scholar
  40. 40.
    Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin – a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93:350–84.PubMedGoogle Scholar
  41. 41.
    Cardinali DP, Vacas MI, Boyer EE. Specific binding of melatonin in bovine brain. Endocrinology. 1979;105:437–41.PubMedGoogle Scholar
  42. 42.
    Cardinali DP, Vacas MI, Boyer EE. High affinity binding of melatonin in bovine medial basal hypothalamus. IRCS Med Sci. 1978;6:357.Google Scholar
  43. 43.
    Niles LP, Wong YW, Mishra RK, Brown GM. Melatonin receptors in brain. Eur J Pharmacol. 1979;55:219–20.PubMedGoogle Scholar
  44. 44.
    Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int. 1994;24:101–46.PubMedGoogle Scholar
  45. 45.
    Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994;13:1177–85.PubMedGoogle Scholar
  46. 46.
    Reppert SM, Godson C, Mahle CD, Weaver DR, Slaugenhaupt SA, Gusella JF. Molecular characterization of a second melatonin receptor expressed in human retina and brain: the Mel1b melatonin receptor. Proc Natl Acad Sci U S A. 1995;92:8734–8.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of g protein-coupled melatonin receptors. Nomenclature, classification and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev. 2010;62:343–80.PubMedPubMedCentralGoogle Scholar
  48. 48.
    Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJM, Zisapel N, Cardinali DP. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol. 2008;185:335–53.Google Scholar
  49. 49.
    Weaver DR, Reppert SM. The Mel1a melatonin receptor gene is expressed in human suprachiasmatic nuclei. Neuroreport. 1996;8:109–12.PubMedGoogle Scholar
  50. 50.
    Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.PubMedGoogle Scholar
  51. 51.
    von Gall C, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002;309:151–62.Google Scholar
  52. 52.
    Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992;9:380–92.PubMedGoogle Scholar
  53. 53.
    Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol. 2008;586:639–47.PubMedGoogle Scholar
  54. 54.
    Cardinali DP, Lynch HJ, Wurtman RJ. Binding of melatonin to human and rat plasma proteins. Endocrinology. 1972;91:1213–8.PubMedGoogle Scholar
  55. 55.
    Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005;9:11–24.PubMedGoogle Scholar
  56. 56.
    Tetsuo M, Markey SP, Kopin IJ. Measurement of 6-hydroxymelatonin in human urine and its diurnal variations. Life Sci. 1980;27:105–9.PubMedGoogle Scholar
  57. 57.
    Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005;33:489–94.PubMedGoogle Scholar
  58. 58.
    Luthringer R, Muzet M, Zisapel N, Staner L. The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol. 2009;24:239–49.PubMedGoogle Scholar
  59. 59.
    Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N. Prolonged release melatonin in the treatment of primary insomnia: evaluation of the age cut-off for short- and long-term response. Curr Med Res Opin. 2011;27:87–98.PubMedGoogle Scholar
  60. 60.
    Gorfine T, Assaf Y, Goshen-Gottstein Y, Yeshurun Y, Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006;31:410–8.PubMedGoogle Scholar
  61. 61.
    Walker CK, Gales MA. Melatonin receptor agonists for delirium prevention. Ann Pharmacother. 2017;51:72–8.PubMedGoogle Scholar
  62. 62.
    Edmonds C, Swanoski M. A review of suvorexant, doxepin, ramelteon, and tasimelteon for the treatment of insomnia in geriatric patients. Consult Pharm. 2017;32:156–60.PubMedGoogle Scholar
  63. 63.
    Cardinali DP, Vidal MF, Vigo DE. Agomelatine: its role in the management of major depressive disorder. Clin Med Insights Psychiatry. 2012;4:1–23.Google Scholar
  64. 64.
    Moore RY, Speh JC. GABA is the principal neurotransmitter of the circadian system. Neurosci Lett. 1993;150:112–6.PubMedGoogle Scholar
  65. 65.
    Morin LP. Neuroanatomy of the extended circadian rhythm system. Exp Neurol. 2013;243:4–20.PubMedGoogle Scholar
  66. 66.
    Romijn HJ. The pineal, a tranquillizing organ? Life Sci. 1978;23:2257–73.PubMedGoogle Scholar
  67. 67.
    Rudeen PK, Philo RC, Symmes SK. Antiepileptic effects of melatonin in the pinealectomized Mongolian gerbil. Epilepsia. 1980;21:149–54.PubMedGoogle Scholar
  68. 68.
    Albertson TE, Peterson SL, Stark LG, Lakin ML, Winters WD. The anticonvulsant properties of melatonin on kindled seizures in rats. Neuropharmacology. 1981;20:61–6.PubMedGoogle Scholar
  69. 69.
    Borowicz KK, Kaminski R, Gasior M, Kleinrok Z, Czuczwar SJ. Influence of melatonin upon the protective action of conventional anti-epileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol. 1999;9:185–90.PubMedGoogle Scholar
  70. 70.
    Forcelli PA, Soper C, Duckles A, Gale K, Kondratyev A. Melatonin potentiates the anticonvulsant action of phenobarbital in neonatal rats. Epilepsy Res. 2013;107:217–23.PubMedGoogle Scholar
  71. 71.
    Golombek DA, Escolar E, Burin LJ, De Brito Sanchez MG, Fernandez DD, Cardinali DP. Chronopharmacology of melatonin: inhibition by benzodiazepine antagonism. Chronobiol Int. 1992;9:124–31.PubMedGoogle Scholar
  72. 72.
    Golombek DA, Fernandez DD, De Brito Sanchez MG, Burin L, Cardinali DP. Time-dependent anticonvulsant activity of melatonin in hamsters. Eur J Pharmacol. 1992;210:253–8.PubMedGoogle Scholar
  73. 73.
    Munoz-Hoyos A, Sanchez-Forte M, Molina-Carballo A, Escames G, Martin-Medina E, Reiter RJ, Molina-Font JA, Acuña-Castroviejo D. Melatonin’s role as an anticonvulsant and neuronal protector: experimental and clinical evidence. J Child Neurol. 1998;13:501–9.PubMedGoogle Scholar
  74. 74.
    Molina-Carballo A, Munoz-Hoyos A, Sanchez-Forte M, Uberos-Fernandez J, Moreno-Madrid F, Acuña-Castroviejo D. Melatonin increases following convulsive seizures may be related to its anticonvulsant properties at physiological concentrations. Neuropediatrics. 2007;38:122–5.PubMedGoogle Scholar
  75. 75.
    Solmaz I, Gurkanlar D, Gokcil Z, Goksoy C, Ozkan M, Erdogan E. Antiepileptic activity of melatonin in guinea pigs with pentylenetetrazol-induced seizures. Neurol Res. 2009;31:989–95.PubMedGoogle Scholar
  76. 76.
    Fenoglio-Simeone K, Mazarati A, Sefidvash-Hockley S, Shin D, Wilke J, Milligan H, Sankar R, Rho JM, Maganti R. Anticonvulsant effects of the selective melatonin receptor agonist ramelteon. Epilepsy Behav. 2009;16:52–7.PubMedGoogle Scholar
  77. 77.
    Golombek DA, Martini M, Cardinali DP. Melatonin as an anxiolytic in rats: time dependence and interaction with the central GABAergic system. Eur J Pharmacol. 1993;237:231–6.PubMedGoogle Scholar
  78. 78.
    Golombek DA, Escolar E, Burin LJ, De Brito Sanchez MG, Cardinali DP. Time-dependent melatonin analgesia in mice: inhibition by opiate or benzodiazepine antagonism. Eur J Pharmacol. 1991;194:25–30.PubMedGoogle Scholar
  79. 79.
    Pang CS, Tsang SF, Yang JC. Effects of melatonin, morphine and diazepam on formalin-induced nociception in mice. Life Sci. 2001;68:943–51.PubMedGoogle Scholar
  80. 80.
    Papp M, Litwa E, Gruca P, Mocaer E. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 2006;17:9–18.PubMedGoogle Scholar
  81. 81.
    Ulugol A, Dokmeci D, Guray G, Sapolyo N, Ozyigit F, Tamer M. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: possible involvements of the L-arginine-NO pathway and opioid system. Life Sci. 2006;78:1592–7.PubMedGoogle Scholar
  82. 82.
    Srinivasan V, Pandi-Perumal SR, Spence DW, Moscovitch A, Trakht I, Brown GM, Cardinali DP. Potential use of melatonergic drugs in analgesia: mechanisms of action. Brain Res Bull. 2010;81:362–71.PubMedGoogle Scholar
  83. 83.
    Zhang L, Guo HL, Zhang HQ, Xu TQ, He B, Wang ZH, Yang YP, Tang XD, Zhang P, Liu FE. Melatonin prevents sleep deprivation-associated anxiety-like behavior in rats: role of oxidative stress and balance between GABAergic and glutamatergic transmission. Am J Transl Res. 2017;9:2231–42.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Anton-Tay F. Melatonin: effects on brain function. Adv Biochem Psychopharmacol. 1974;11:315–24.PubMedGoogle Scholar
  85. 85.
    Acuña Castroviejo D, Rosenstein RE, Romeo HE, Cardinali DP. Changes in gamma-aminobutyric acid high affinity binding to cerebral cortex membranes after pinealectomy or melatonin administration to rats. Neuroendocrinology. 1986;43:24–31.PubMedGoogle Scholar
  86. 86.
    Acuña Castroviejo D, Lowenstein P, Rosenstein RE, Cardinali DP. Diurnal variations of benzodiazepine binding in rat cerebral cortex: disruption by pinealectomy. J Pineal Res. 1986;3:101–9.PubMedGoogle Scholar
  87. 87.
    Lowenstein PR, Rosenstein R, Cardinali DP. Melatonin reverses pinealectomy-induced decrease of benzodiazepine binding in rat cerebral cortex. Neurochem Int. 1985;7:675–81.PubMedGoogle Scholar
  88. 88.
    Coloma FM, Niles LP. Melatonin enhancement of [3H]-gamma-aminobutyric acid and [3H]muscimol binding in rat brain. Biochem Pharmacol. 1988;37:1271–4.PubMedGoogle Scholar
  89. 89.
    Rosenstein RE, Cardinali DP. Melatonin increases in vivo GABA accumulation in rat hypothalamus, cerebellum, cerebral cortex and pineal gland. Brain Res. 1986;398:403–6.PubMedGoogle Scholar
  90. 90.
    Rosenstein RE, Estevez AG, Cardinali DP. Time-dependent effect of melatonin on glutamic acid decarboxylase activity and CI influx in rat hypothalamus. J Neuroendocrinol. 1989;1:443–7.PubMedGoogle Scholar
  91. 91.
    Niles L. Melatonin interaction with the benzodiazepine-GABA receptor complex in the CNS. Adv Exp Med Biol. 1991;294:267–77.PubMedGoogle Scholar
  92. 92.
    Niles LP, Peace CH. Allosteric modulation of t-[35S]butylbicyclophosphorothionate binding in rat brain by melatonin. Brain Res Bull. 1990;24:635–8.PubMedGoogle Scholar
  93. 93.
    Stankov B, Biella G, Panara C, Lucini V, Capsoni S, Fauteck J, Cozzi B, Fraschini F. Melatonin signal transduction and mechanism of action in the central nervous system: using the rabbit cortex as a model. Endocrinology. 1992;130:2152–9.PubMedGoogle Scholar
  94. 94.
    Wan Q, Man HY, Liu F, Braunton J, Niznik HB, Pang SF, Brown GM, Wang YT. Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors. Nat Neurosci. 1999;2:401–3.PubMedGoogle Scholar
  95. 95.
    Shibata S, Cassone VM, Moore RY. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci Lett. 1989;97:140–4.PubMedGoogle Scholar
  96. 96.
    Wu FS, Yang YC, Tsai JJ. Melatonin potentiates the GABA(A) receptor-mediated current in cultured chick spinal cord neurons. Neurosci Lett. 1999;260:177–80.PubMedGoogle Scholar
  97. 97.
    Li GL, Li P, Yang XL. Melatonin modulates gamma-aminobutyric acid(A) receptor-mediated currents on isolated carp retinal neurons. Neurosci Lett. 2001;301:49–53.PubMedGoogle Scholar
  98. 98.
    Cheng XP, Sun H, Ye ZY, Zhou JN. Melatonin modulates the GABAergic response in cultured rat hippocampal neurons. J Pharmacol Sci. 2012;119:177–85.PubMedGoogle Scholar
  99. 99.
    Cassone VM, Chesworth MJ, Armstrong SM. Entrainment of rat circadian rhythms by daily injection of melatonin depends upon the hypothalamic suprachiasmatic nuclei. Physiol Behav. 1986;36:1111–21.PubMedGoogle Scholar
  100. 100.
    Golombek DA, Escolar E, Cardinali DP. Melatonin-induced depression of locomotor activity in hamsters: time-dependency and inhibition by the central-type benzodiazepine antagonist Ro 15-1788. Physiol Behav. 1991;49:1091–7.PubMedGoogle Scholar
  101. 101.
    Guardiola-Lemaitre B, Lenegre A, Porsolt RD. Combined effects of diazepam and melatonin in two tests for anxiolytic activity in the mouse. Pharmacol Biochem Behav. 1992;41:405–8.PubMedGoogle Scholar
  102. 102.
    Dubocovich ML, Mogilnicka E, Areso PM. Antidepressant-like activity of the melatonin receptor antagonist, luzindole (N-0774), in the mouse behavioral despair test. Eur J Pharmacol. 1990;182:313–25.PubMedGoogle Scholar
  103. 103.
    Wang F, Li J, Wu C, Yang J, Xu F, Zhao Q. The GABA(A) receptor mediates the hypnotic activity of melatonin in rats. Pharmacol Biochem Behav. 2003;74:573–8.PubMedGoogle Scholar
  104. 104.
    Tenn CC, Niles LP. Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology. 1997;36:1659–63.PubMedGoogle Scholar
  105. 105.
    Zhang W, Li F, Zhang T. Relationship of nocturnal concentrations of melatonin, gamma-aminobutyric acid and total antioxidants in peripheral blood with insomnia after stroke: study protocol for a prospective non-randomized controlled trial. Neural Regen Res. 2017;12:1299–307.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Rogers NL, Kennaway DJ, Dawson D. Neurobehavioural performance effects of daytime melatonin and temazepam administration. J Sleep Res. 2003;12:207–12.PubMedGoogle Scholar
  107. 107.
    Otmani S, Demazieres A, Staner C, Jacob N, Nir T, Zisapel N, Staner L. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. Hum Psychopharmacol. 2008;23:693–705.PubMedGoogle Scholar
  108. 108.
    Otmani S, Metzger D, Guichard N, Danjou P, Nir T, Zisapel N, Katz A. Effects of prolonged-release melatonin and zolpidem on postural stability in older adults. Hum Psychopharmacol. 2012;27:270–6.PubMedGoogle Scholar
  109. 109.
    Litvinenko IV, Krasakov IV, Tikhomirova OV. Sleep disorders in Parkinson’s disease without dementia: a comparative randomized controlled study of melatonin and clonazepam. Zh Nevropatol Psikhiatr Im S S Korsakova. 2012;112:26–30.Google Scholar
  110. 110.
    Pokharel K, Tripathi M, Gupta PK, Bhattarai B, Khatiwada S, Subedi A. Premedication with oral alprazolam and melatonin combination: a comparison with either alone – a randomized controlled factorial trial. Biomed Res Int. 2014;2014:356964.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Arbon EL, Knurowska M, Dijk DJ. Randomised clinical trial of the effects of prolonged-release melatonin, temazepam and zolpidem on slow-wave activity during sleep in healthy people. J Psychopharmacol. 2015;29:764–76.PubMedGoogle Scholar
  112. 112.
    Mistraletti G, Umbrello M, Sabbatini G, Miori S, Taverna M, Cerri B, Mantovani ES, Formenti P, Spanu P, D’Agostino A, Salini S, Morabito A, Fraschini F, Reiter RJ, Iapichino G. Melatonin reduces the need for sedation in ICU patients. A randomized controlled trial. Minerva Anestesiol. 2015;81:1298–310.PubMedGoogle Scholar
  113. 113.
    Gitto E, Marseglia L, D’Angelo G, Manti S, Crisafi C, Montalto AS, Impellizzeri P, Reiter RJ, Romeo C. Melatonin versus midazolam premedication in children undergoing surgery: a pilot study. J Paediatr Child Health. 2016;52:291–5.PubMedGoogle Scholar
  114. 114.
    Fainstein I, Bonetto A, Brusco LI, Cardinali DP. Effects of melatonin in elderly patients with sleep disturbance. A pilot study. Curr Ther Res. 1997;58:990–1000.Google Scholar
  115. 115.
    Dagan Y, Zisapel N, Nof D, Laudon M, Atsmon J. Rapid reversal of tolerance to benzodiazepine hypnotics by treatment with oral melatonin: a case report. Eur Neuropsychopharmacol. 1997;7:157–60.PubMedGoogle Scholar
  116. 116.
    Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159:2456–60.PubMedGoogle Scholar
  117. 117.
    Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI, Cardinali DP. Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res. 2001;30:34–42.PubMedGoogle Scholar
  118. 118.
    Cardinali DP, Gvozdenovich E, Kaplan MR, Fainstein I, Shifis HA, Perez LS, Albornoz L, Negri A. A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. Neuro Endocrinol Lett. 2002;23:55–60.PubMedGoogle Scholar
  119. 119.
    Vissers FH, Knipschild PG, Crebolder HF. Is melatonin helpful in stopping the long-term use of hypnotics? A discontinuation trial. Pharm World Sci. 2007;29:641–6.PubMedPubMedCentralGoogle Scholar
  120. 120.
    Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res. 2007;43:404–9.PubMedGoogle Scholar
  121. 121.
    Peles E, Hetzroni T, Bar-Hamburger R, Adelson M, Schreiber S. Melatonin for perceived sleep disturbances associated with benzodiazepine withdrawal among patients in methadone maintenance treatment: a double-blind randomized clinical trial. Addiction. 2007;102:1947–53.PubMedGoogle Scholar
  122. 122.
    Garzon C, Guerrero JM, Aramburu O, Guzman T. Effect of melatonin administration on sleep, behavioral disorders and hypnotic drug discontinuation in the elderly: a randomized, double-blind, placebo-controlled study. Aging Clin Exp Res. 2009;21:38–42.PubMedGoogle Scholar
  123. 123.
    Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1:280–91.PubMedPubMedCentralGoogle Scholar
  124. 124.
    Kunz D, Bineau S, Maman K, Milea D, Toumi M. Benzodiazepine discontinuation with prolonged-release melatonin: hints from a German longitudinal prescription database. Expert Opin Pharmacother. 2012;13:9–16.PubMedGoogle Scholar
  125. 125.
    Hajak G, Lemme K, Zisapel N. Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin. Int Clin Psychopharmacol. 2015;30:36–42.PubMedGoogle Scholar
  126. 126.
    Baandrup L, Lindschou J, Winkel P, Gluud C, Glenthoj BY. Prolonged-release melatonin versus placebo for benzodiazepine discontinuation in patients with schizophrenia or bipolar disorder: a randomised, placebo-controlled, blinded trial. World J Biol Psychiatry. 2016;17(7):514–24.Google Scholar
  127. 127.
    Baandrup L, Fasmer OB, Glenthoj BY, Jennum PJ. Circadian rest-activity rhythms during benzodiazepine tapering covered by melatonin versus placebo add-on: data derived from a randomized clinical trial. BMC Psychiatry. 2016;16:348.PubMedPubMedCentralGoogle Scholar
  128. 128.
    Baandrup L, Glenthoj BY, Jennum PJ. Objective and subjective sleep quality: melatonin versus placebo add-on treatment in patients with schizophrenia or bipolar disorder withdrawing from long-term benzodiazepine use. Psychiatry Res. 2016;240:163–9.PubMedGoogle Scholar
  129. 129.
    Baandrup L, Fagerlund B, Glenthoj B. Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo. Eur Arch Psychiatry Clin Neurosci. 2017;267:163–71.PubMedGoogle Scholar
  130. 130.
    Hansen MV, Halladin NL, Rosenberg J, Gogenur I, Moller AM. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. 2015;4:CD009861.Google Scholar
  131. 131.
    Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Siren AL, Hardeland R, Bahr M, Nave KA, Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006;41:313–23.PubMedGoogle Scholar
  132. 132.
    Chahbouni M, Escames G, Venegas C, Sevilla B, Garcia JA, Lopez LC, Munoz-Hoyos A, Molina-Carballo A, Acuña-Castroviejo D. Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res. 2010;48:282–9.PubMedGoogle Scholar
  133. 133.
    Waldhauser F, Waldhauser M, Lieberman HR, Deng MH, Lynch HJ, Wurtman RJ. Bioavailability of oral melatonin in humans. Neuroendocrinology. 1984;39:307–13.PubMedGoogle Scholar
  134. 134.
    Voordouw BC, Euser R, Verdonk RE, Alberda BT, de Jong FH, Drogendijk AC, Fauser BC, Cohen M. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab. 1992;74:108–17.PubMedGoogle Scholar
  135. 135.
    Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, Pelzl LH, Gotthardt DN, Cekauskas A, Manikas M, Mikalauskas S, Mikalauskene L, Bruns H, Zorn M, Weigand MA, Buchler MW, Schemmer P. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;50:381–8.PubMedGoogle Scholar
  136. 136.
    Lopez-Gonzalez A, Alvarez-Sanchez N, Lardone PJ, Cruz-Chamorro I, Martinez-Lopez A, Guerrero JM, Reiter RJ, Carrillo-Vico A. Melatonin treatment improves primary progressive multiple sclerosis: a case report. J Pineal Res. 2015;58:173–7.PubMedGoogle Scholar
  137. 137.
    Cardinali DP, Golombek DA. Let there be sleep – on time. Lancet. 2009;373:439–41.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Daniel E. Vigo
    • 1
    • 2
    • 3
  • Daniel P. Cardinali
    • 3
  1. 1.Chronophysiology Lab, Institute for Biomedical Research (BIOMED)Pontifical Catholic University of Argentina (UCA) and National Research Council (CONICET)Buenos AiresArgentina
  2. 2.Research Group on Health PsychologyFaculty of Psychology and Educational Sciences, Katholieke Universiteit LeuvenLeuvenBelgium
  3. 3.Teaching and Research DepartmentFaculty of Medical Sciences, Pontifical Catholic University of Argentina (UCA)Buenos AiresArgentina

Personalised recommendations